Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7090808 | 0.86 | NPSR1 (0.37) | NPSR1MEN1KMT2A | |
| SCHEMBL22190208 | 0.80 | MEN1 (0.35) | NPSR1MEN1KMT2A | |
| SCHEMBL1342011 | 0.79 | NPSR1 (0.40) | NPSR1MEN1KMT2A | |
| SCHEMBL1341779 | 0.76 | NPSR1 (0.47) | NPSR1MEN1KMT2A | |
| SCHEMBL1340687 | 0.76 | NPSR1 (0.42) | NPSR1MEN1KMT2A | |
| SCHEMBL10002389 | 0.74 | MAPK1 (0.33) | KMT2A | |
| SCHEMBL595761 | 0.74 | NPSR1 (0.45) | NPSR1MEN1KMT2A | |
| SCHEMBL1088376 | 0.74 | DGAT1 (0.36) | — | |
| SCHEMBL3923179 | 0.73 | NPSR1 (0.34) | NPSR1MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL27820705 | 0.72 | NPSR1 (0.44) | NPSR1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1648893-B1 | NICOTINE ADDICTION REDUCING HETEROARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2009-09-23 | — | — | EP | disclosed |
| US-7456177-B2 | Heteroaryl fused azapolycyclic compounds which bind to neuronal nicotinic acetylcholine specific receptor sites, and which are useful in modulating cholinergic function, for for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, therapy | PFIZER INC. (US) | 2008-11-25 | — | — | US | disclosed |
| US-7122534-B2 | Aryl fused azapolycyclic compounds | PFIZER INC (US) | 2006-10-17 | — | — | US | disclosed |
| EP-1648893-A1 | NICOTINE ADDICTION REDUCING HETEROARYL FUSED AZAPOLYCYCLIC COMPOUNDS | Pfizer Products Inc. (US) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005007655-A1 | NICOTINE ADDICTION REDUCING HETEROARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 2005-01-27 | — | — | WO | disclosed |
| US-20050020830-A1 | Heteroaryl fused azapolycyclic compounds which bind to neuronal nicotinic acetylcholine specific receptor sites, and which are useful in modulating cholinergic function, for for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, therapy | PFIZER INC | 2005-01-27 | — | — | US | disclosed |
| US-20040167149-A1 | Aryl fused azapolycyclic compounds | PFIZER INC | 2004-08-26 | — | — | US | disclosed |
| US-6706702-B2 | FOR THERAPY OF NEUROLOGICAL AND PSYCHOLOGICAL DISORDERS | PFIZER INC. | 2004-03-16 | — | — | US | disclosed |
| EP-1076650-B1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PROD INC (US) | 2004-02-04 | — | — | EP | disclosed |
| US-20030130261-A1 | Aryl fused azapolycyclic compounds | PFIZER INC | 2003-07-10 | — | — | US | disclosed |
| US-20030008890-A1 | Aryl fused azapolycyclic compounds | COE JOTHAM WADSWORTH (US) | 2003-01-09 | — | — | US | disclosed |
| US-6462035-B1 | BINDING TO NEURONAL NICOTINIC ACETYLCHOLINE SPECIFIC RECEPTOR; MODULATING CHOLINERGIC FUNCTION; REDUCING NICOTINE ADDICTION; INFLAMMATORY AND IRRITABLE BOWEL SYNDROME, SPASTIC DYSTONIA, CHRONIC AND ACUTE PAIN, EATING DISORDERS | PFIZER INC. | 2002-10-08 | — | — | US | disclosed |
| EP-1076650-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | Pfizer Products Inc. (US) | 2001-02-21 | — | — | EP | disclosed |
| WO-1999055680-A1 | ARYL FUSED AZAPOLYCYCLIC COMPOUNDS | PFIZER PRODUCTS INC. (US) | 1999-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130261-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, GRIN3A | NPSR1 143/4885MEN1 1550/4885KMT2A 363/4885 |
| US-20050020830-A1 | Heteroaryl fused azapolycyclic compounds which bind to neuronal nicotinic acetylcholine specific receptor sites, and which are useful in modulating cholinergic function, for for reducing nicotine addiction or aiding in the cessation or lessening of tobacco use in a mammal, therapy | CHRNA2, CHRNA3, CHRNB2 | NPSR1 155/4885MEN1 2844/4885KMT2A 1592/4885 |
| US-20030008890-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, NR3C1 | NPSR1 161/4885MEN1 1490/4885KMT2A 359/4885 |
| US-20040167149-A1 | Aryl fused azapolycyclic compounds | GRIN2C, GRIN2A, NR3C1 | NPSR1 161/4885MEN1 1490/4885KMT2A 359/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.